Medical Radiology and Radiation Safety. 2020. Vol. 65. No. 1. P.42–47

V.M. Sotnikov, G.A. Panshin, V.A. Solodkiy, V.D. Chkhikvadze, V.P. Kharchenko, N.V. Nudnov, S.D. Trotsenko, V.N. Vasilev, A.Yu. Smyslov, A.A. Morgunov

The Overall Survival of Non-Small Cell Lung Cancer Patients Group pN2
after Radical Surgery and Postoperative Radiotherapy

Russian Scientific Center of Roentgenoradiology, Moscow, Russia
E-mail: Этот адрес электронной почты защищен от спам-ботов. У вас должен быть включен JavaScript для просмотра.


Purpose: Comparative analysis of the overall survival (OS) in different subgroups of the patients with non-small cell lung cancer (NSCLC) with affected mediastinal lymph nodes (pN2) after surgical and combined treatment using postoperative radiotherapy (PORT).

Material and methods: A comparative assessment of the overall survival of 243 patients with NSCLC stages IIIA, IIIB (рT1–4N2M0) was carried out: the I group – 79 patients after radical (R0) surgical treatment (lobe/bilobectomy, pulmonectomy with ipsilateral mediastinal lymph node dissection) and the second group – 164 patients after the combined modality therapy with the same volume of surgery and postoperative radiotherapy in the mode of hypofractionation (daily dose 3 Gy, 5 times a week, TD = 36–39 Gy (EQD2 = 43.2–46.8 Gy, α/β = 3) or classical fractionation (2 Gy, 5 times a week, TD = 44 Gy). We analyzed subgroups of men and women, patients younger than 60 years and older, with central and peripheral cancer, squamous cell carcinoma and adenocarcinoma, with different gradation of tumors according to the criterion T (pT1–4).

Results: In the compared groups, 2-year and 5-year OS was significantly higher in the PORT group (62.4 and 31.6 vs 44.8 % and 12.3 %, p = 0.0028), at the expense of male patients (62.4 and 31.6 % vs 44.8 and 12.3 %, p = 0.0028), patients with central cancer (59.2 and 43.7 % vs 36.3 % and n/a, p = 0.0023), patients with squamous cell carcinoma (64.0 % and 43.1 % vs 42.3 % and 6.7 %, p = 0.0006), patients older than 60 years (74.8 and 46.2 % vs 45.1 % and n/a, p = 0.007). A more detailed analysis revealed that PORT significantly increased 2- and 5-year OS in the central squamous cell carcinoma of the lung (67.3 and 53.0 % vs. 33.3 and 0 %, respectively, p = 0.0013), and in pT3–4 tumors (2-year OS 57.1 vs. 36.4 %, respectively, p = 0.0102). There was only a tendency of increasing OS after the PORT in T2 tumors (5-year OS 31.1 vs 15.4 %, respectively, p = 0.1319). In T1 tumors, no differences in OS were found, possibly due to the small number of cases (27). In peripheral squamous cell carcinoma there was a statistically insignificant increasing of 5-year OS – 7 %. There was no significant differences in OS survival were obtained in central and peripheral lung adenocarcinoma between the I and II groups.

Conclusion: In the patients with non-small cell lung cancer pN2, radically operated (R0) in the volume of lobe/bilobectomy, pulmonectomy with ipsilateral mediastinal lymph node dissection, PORT can be recommended for central squamous cell carcinoma pT1–4. In the patients with peripheral squamous cell carcinoma, PORT can be discussed for the patients with individually assessed high risk of the locoregional relapse. PORT, within the scope of irradiation and total doses used in this study, has no age restrictions. The feasibility of PORT for radically operated patients with pN2 lung adenocarcinoma requires further study.

Key words: non-small cell lung cancer, surgical treatment, postoperative radiation therapy, overall survival

For citation: Sotnikov VM, Panshin GA, Solodkiy VA, Chkhikvadze VD, Kharchenko VP, Nudnov NV, Trotsenko SD, Vasilev VN, Smyslov AYu, Morgunov AA. The Overall Survival of Non-Small Cell Lung Cancer Patients Group pN2 after Radical Surgery and Postoperative Radiotherapy. Medical Radiology and Radiation Safety. 2020;65(1):42-47. (In Russ.).

DOI: 10.12737/1024-6177-2020-65-1-42-47

Список литературы / References

  1. Feng W, Zhang Q, Fu X-L, et al. The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume. BMC Cancer. 2015;15:348-57. DOI: 10.1186/s12885-015-1326-6.
  2. Robinson CG, Patel AP, Bradley JD, et al. Postoperative Radiotherapy for Pathologic N2 Non–Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: A Review of the National Cancer Data Base. J Clin Oncol. 2015;33(8):870-6.
  3. Троценко СД, Солодкий ВА, Сотников ВМ, и др. Результаты хирургического и комбинированного лечения немелкоклеточного рака легкого с послеоперационной лучевой терапией в режиме гипофракционирования. Общая и болезнь-специфичная выживаемость. Вопросы онкологии. 2015(1):71-6. [Trotsenko SD, Solodky VA, Sotnikov VM et al. The results of surgical and combined treatment for non-small cell lung cancer with postoperative radiotherapy in the mode of hypofractioning. Overall and disease-specific survival. Problems in Oncology. 2015(1):71-6. (In Russ.)].
  4. Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28 (Suppl. 4): iv1–iv21.
  5. Bezjak A, Temin S, Franklin G, et al. Definitive and Adjuvant Radiotherapy in Locally Advanced Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. J Clin Oncol. 2015;33(18):2100-5. DOI: 10.1200/JCO.2014.59.2360.
  6. Billiet C, Dirix P, Meijnders P, Ruysscher DD, et al. Prognostic Models for Patient Selection in Postoperative Radiotherapy: Ready for Use? J Thorac Oncol. 2018;13(12):1809-11.
  7. Gomez JA, Gonzalez F, Counago et al. Evidence-based recommendations of postoperative radiotherapy in lung cancer from Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society. Clin Transl Oncol. 2016;18:331-41. DOI: 10.1007/s12094-015-1374-z.
  8. Mikell JL, Gillespie TW, Hall WA, et al. Post-operative radiotherapy (PORT) is associated with better survival in non-small cell lung cancer with involved N2 lymph nodes. J Thorac Oncol. 2015;10(3):462-71.
  9. Hui Z, Dai H, Liang J, et al. Selection of Proper Candidates with Resected IIIA-N2 Non-small Cell Lung Cancer for Postoperative Radiotherapy: A New Prediction Model. Int J Radiat Oncol Biol Phys. 2008;72(1). Suppl. A.1015.
  10. Cox JD, Scott CB, Byhardt RW, et al. Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): analysis of radiation therapy oncology group (RTOG) trials. Int J Radiat Oncol Biol Phys. 1999;43(3):505-9.
  11. Yano T, Okamoto T, Fukuyama S, Maehara Y. Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer. World J Clin Oncol. 2014;5(5):1048-54.

PDF (RUS) Full-text article (in Russian)

Conflict of interest. The authors declare no conflict of interest.

Financing. The study had no sponsorship.

Contribution. Article was prepared with equal participation of the authors.

Article received: 21.05.2019. Accepted for publication: 11.12.2019.